p-toluenesulfonic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-toluenesulfonic acid
• 英文别名: 4-methylbenzenesulfinate；(4-methylphenyl)-dioxo-λ6-sulfane
• 化学式: C₇H₈O₂S
• 分子量: 156.205
• InChiKey: VMBAUQZYJZISFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.97
• 重原子数：
  10.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  34.14
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  p-toluenesulfonic acid 生成 sodium 4-methylbenzenesulfinate
  参考文献：
  名称：

  RUSSELL, G. A.;ROS, F., J. AMER. CHEM. SOC., 1985, 107, N 8, 2506-2511

  摘要：

  DOI：
• 作为产物：
  描述：

  (Z)-diethylamino-(4-methylphenyl)sulfonyloxyimino-oxidoazanium 在 ethyl thiolate 作用下， 以 氘代二甲亚砜 为溶剂， 生成 p-toluenesulfonic acid
  参考文献：
  名称：

  Preparation and Reactivity of O²-Sulfonated Diazeniumdiolates

  摘要：

  We report the facile preparation of O-2-sulfonated diazeniumdiolates and mechanistic investigation of their reactions with representative nucleophiles. This new class of compounds extends the range of O-2-substituted diazeniumdiolates available for potential applications in research and medicine.

  DOI：

  10.1021/jo026656n
• 作为试剂：
  描述：

  3-amino-6-methyl-4-phenylpyridin-2(1H)-one 、 原甲酸三乙酯 在 p-toluenesulfonic acid 作用下， 以 甲苯 为溶剂， 生成 5-methyl-7-phenyl[1,3]oxazolo[5,4-b]pyridine
  参考文献：
  名称：

  5-Ethyl-5,6-dihydrobenzo[c] [1,7]naphthyridin-4(3H)-ones – A new class of fluorescent dyes

  摘要：

  Reduction of benzo[c] [1,7]naphthyridin-4(3H)-ones with sodium borohydride in acetic acid led to a series of 5-ethyl-5,6-dihydrobenzo[c] [1,7]naphthyridin-4(3H)-ones. The latter are photostable fluorophores emitting in the green region of the visible spectrum with a fluorescence quantum yield of up to 0.43 and a Stokes shift of up to 133 nm, containing an “embedded” amino acid motif. The localization

  DOI：

  10.1016/j.dyepig.2022.110388

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] QUINOLINE AND QUINAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS QUINOLÉINE ET QUINAZOLINE
  申请人：ACERTA PHARMA BV

  公开号：WO2016055982A1

  公开（公告）日：2016-04-14

  In some embodiments, the invention relates to quinazoline and quinoline compounds of Formula I: (I) or a pharmaceutically acceptable salt thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, in some embodiments, the present invention relates to quinazoline and quinoline compounds, pharmaceutical compositions thereof, and the use of the compounds and pharmaceutical compositions in the treatment of Bruton's tyrosine kinase (BTK) mediated disorders.

  在某些实施例中，该发明涉及式I的喹唑啉和喹啉化合物：(I)或其药用可接受盐，或者涉及包含这些化合物的药物组合物以及它们在治疗中的应用。具体而言，在某些实施例中，本发明涉及喹唑啉和喹啉化合物、其药物组合物以及这些化合物和药物组合物在治疗布鲁顿氨基酸激酶（BTK）介导的疾病中的应用。
• NOVEL GPR119 AGONIST COMPOUNDS
  申请人：Mankind Pharma Ltd.

  公开号：US20170291894A1

  公开（公告）日：2017-10-12

  The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.

  本发明涉及公式（I）的新化合物，其制备方法以及包含这些化合物的组合物。
• [EN] COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF<br/>[FR] COMPOSÉS COMPRENANT UN LIEUR CLIVABLE ET LEURS UTILISATIONS
  申请人：INTOCELL INC

  公开号：WO2019008441A1

  公开（公告）日：2019-01-10

  Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

  提供了一种包括可切割连接物的化合物，其用途，以及用于制备该化合物的中间体化合物，更具体地，本发明的包括可切割连接物的化合物可能包括具有特定功能或活性的活性剂（例如，药物，毒素，配体，用于检测的探针等），能够选择性释放活性剂的SO2官能团，以及通过外部刺激触发化学反应，物理化学反应和/或生物反应的官能团，并且还可以包括具有与所需靶受体结合特异性的配体（例如，寡肽，多肽，抗体等）。
• [EN] 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA 3-PHOSPHOGLYCÉRATE DÉSHYDROGÉNASE ET LEURS UTILISATIONS
  申请人：RAZE THERAPEUTICS INC

  公开号：WO2017156181A1

  公开（公告）日：2017-09-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。